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ABSTRACT Infection control effectiveness evaluations require detailed epidemiolog-
ical and microbiological data. We analyzed the genomic proﬁles of carbapenem-
nonsusceptible Pseudomonas aeruginosa (CNPA) strains collected from two intensive
care units (ICUs) in the national referral hospital in Jakarta, Indonesia, where a multi-
faceted infection control intervention was applied. We used clinical data combined
with whole-genome sequencing (WGS) of systematically collected CNPA to infer the
transmission dynamics of CNPA strains and to characterize their resistome. We found
that the number of CNPA transmissions and acquisitions by patients was highly vari-
able over time but that, overall, the rates were not signiﬁcantly reduced by the in-
tervention. Environmental sources were involved in these transmissions and acquisi-
tions. Four high-risk international CNPA clones (ST235, ST823, ST375, and ST446)
dominated, but the distribution of these clones changed signiﬁcantly after the inter-
vention was implemented. Using resistome analysis, carbapenem resistance was ex-
plained by the presence of various carbapenemase-encoding genes (blaGES-5,
blaVIM-2-8, and blaIMP-1-7-43) and by mutations within the porin OprD. Our results re-
veal for the ﬁrst time the dynamics of P. aeruginosa antimicrobial resistance (AMR)
proﬁles in Indonesia and additionally show the utility of WGS in combination with
clinical data to evaluate the impact of an infection control intervention. (This study
has been registered at www.trialregister.nl under registration no. NTR5541).
IMPORTANCE In low-to-middle-income countries such as Indonesia, work in in-
tensive care units (ICUs) can be hampered by lack of resources. Conducting large
epidemiological studies in such settings using genomic tools is rather challenging.
Still, we were able to systematically study the transmissions of carbapenem-
nonsusceptible strains of P. aeruginosa (CNPA) within and between ICUs, before and
after an infection control intervention. Our data show the importance of the broad
dissemination of the internationally recognized CNPA clones, the relevance of envi-
ronmental reservoirs, and the mixed effects of the implemented intervention; it led
to a profound change in the clonal make-up of CNPA, but it did not reduce the pa-
tients’ risk of CNPA acquisitions. Thus, CNPA epidemiology in Indonesian ICUs is part
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of a global expansion of multiple CNPA clones that remains difﬁcult to control by in-
fection prevention measures.
KEYWORDS Pseudomonas aeruginosa, intensive care units, infection control, single
nucleotide polymorphism, Indonesia, microbial drug resistance
Pseudomonas aeruginosa is especially dreaded as one of the leading species causinghealth care-associated infections (1, 2). P. aeruginosa is an opportunistic human
pathogen with a remarkably versatile genome, which allows it to adapt to a wide range
of environments and conditions and, consequently, to survive in a variety of niches. This
is mainly due to traits encoded in its accessory genome, which includes genes coding
for antimicrobial resistance (AMR), a great diversity of metabolic pathways, and viru-
lence factors (3). AMR is a major concern in clinical P. aeruginosa isolates, as almost 31%
of all invasive isolates are resistant to at least one of the main antimicrobial groups
tested, according to the most recent AMR surveillance report by the European Centre
for Disease Prevention and Control (ECDC) (4). Additionally, a limited number of P.
aeruginosa clones with multidrug resistance (MDR) proﬁles are particularly worrisome
since they have been shown to have achieved nearly global expansion (5, 6). Especially
in low-to-middle-income countries, MDR P. aeruginosa contributes to in-hospital mor-
tality (7, 8). Gathering as much clinical and microbiological information as possible with
respect to these isolates is essential to inform nosocomial infection control and
surveillance procedures.
During recent years, whole-genome sequencing (WGS) has developed rapidly into a
reference tool for outbreak management (9–12). However, there is not a common
standardized and accepted methodology to infer bacterial transmissions during out-
break investigations from WGS data. This is troublesome, especially when the WGS
approach is implemented in regions of the world where MDR and extensively drug-
resistant (XDR) microorganisms are already endemic.
The aim of this study was to assess nosocomial transmission of carbapenem-
nonsusceptible P. aeruginosa (CNPA) using WGS in combination with detailed clinical
data from intensive care unit (ICU) patients of the national referral hospital of Indonesia.
CNPA isolates were systematically collected before and after an infection control
intervention so that we could study its effect on the dynamics of transmission of CNPA
in this setting in detail. Additionally, we highlight the main P. aeruginosa clones found
as well as their resistomes. Risk factors for the carriage and acquisition of CNPA and its
effect on patients’ outcomes have been analyzed and published separately (13).
RESULTS
A total of 412 patients were included in the study during the preintervention phase
(188 were admitted to the adult ICU and 224 to the emergency room ICU [ER-ICU]), and
at least one CNPA strain was isolated from 51 (12.4%) patients. A total of 363 patients
(adult ICU, 133; ER-ICU, 230) were included during the postintervention phase, and at
least one CNPA strain was isolated from 52 (14.3%) patients (8). Risk factors, including
antibiotic usage, and patient outcomes of CNPA carriage and acquisition during ICU
stay are reported elsewhere (13). A total of 119 CNPA strains were isolated during the
preintervention phase, here deﬁned as the “preintervention phase” set, which included
12 environmental isolates. 118 CNPA strains were isolated during the postintervention
phase, here named the “postintervention phase” set, including 3 environmental iso-
lates. Note that the two strain collections contained multiple CNPA isolates from 51
patients. In order to avoid overrepresentation of speciﬁc genotypes, in the indicated
calculations we used only the ﬁrst isolate per unique genotype per patient (see below
and Table S3).
Phenotypic identiﬁcation and antibiotic susceptibility testing (AST) of the P.
aeruginosa strains. Vitek mass spectrometry (MS) conﬁrmed the correct identiﬁcation
of all P. aeruginosa isolates (data not shown). A total of 130/237 (54.9%) isolates were
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resistant to all antibiotics tested. Details of the results of susceptibility testing are
presented at the isolate level in Table S1 in the supplemental material.
Sequencing statistics and assembly quality. The median N50 value was
225,489 bp (interquartile range [IQR], 195,941 to 269,325 bp), and the median number
of contigs was 114 (IQR, 72 to 148). Genomes sizes ranged from 6.3 Mb to 7.3 Mb.
FastANI identity values for all assemblies were over 98.5%, conﬁrming the correct
species identiﬁcation of all isolates. Detailed sequencing statistics and QUAST (14)
results are summarized in Table S2. The quality criteria were met for all sequences.
In silico MLST. We identiﬁed four major CNPA sequence types (STs) (ST235, ST357,
ST823, and ST446) and three new sequence types (ST3275, ST3277, and ST3278) along
with 12 minor STs (Fig. 1). A goeBURST analysis showed that 17/19 of the sequence
types found belonged to an already-existing P. aeruginosa clonal complex, while
ST1189 and ST3277 were singletons (see Fig. S1 in the supplemental material). We
observed a clear shift in the sequence type distribution between the two phases of
the study: while ST235 was the dominant sequence type in the preintervention phase,
ST357 emerged as the dominant ST in the postintervention phase. Only the main
sequence types and ST244 were present in both phases of the study; the remainder
were detected only in the preintervention phase (ST2951, ST620, ST274, ST1189, ST253,
ST3277, and ST1182) or only in the postintervention phase (ST3278, ST455, ST1076,
ST555, ST312, ST260, and ST3275). Detailed data regarding the MLST proﬁles of all
isolates are provided in Table S3.
Analysis of AMR determinants.We found 102 different AMR-related genes, among
which at least 32 represented acquired resistance genes according to the literature.
Additionally, 70 genes were analyzed with snippy, which brought to light a consider-
able amount of mutations directly related to antibiotic resistance proteins (such as the
AmpC cephalosporinase or penicillin-binding proteins) and mutations in intrinsic genes
such as resistance-nodulation-cell division (RND) efﬂux pumps and regulators. The
mutational resistome obtained with snippy can be found in Table S4. Panel A of Fig. 2
presents a heat map of the AMR determinants found by the use of the Resistance Gene
Identiﬁer-Comprehensive Antibiotic Resistance Database (RGI-CARD) in each genotyp-
ically unique strain in the CNPA collection. Eighteen beta-lactam resistance genes were
detected, among them genes encoding the carbapenem-degrading enzymes blaGES-5
(16/130, 12.3%), blaIMP-1 (1/130, 0.8%), blaIMP-7 (42/130, 32.3%), blaIMP-43 (1/130, 0.8%),
FIG 1 Multilocus sequence type of genotype-corrected CNPA. Sequence types are displayed in the
abscissa axis. The ordinate axis indicates the number of genotype-corrected isolates.
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FIG 2 (A) Antimicrobial resistance heat map of 130 isolates of carbapenem-nonsusceptible P. aeruginosa (CNPA). The x axis contains only AMR
determinants that were variably present in the CNPA collection. The following AMR determinants are not displayed because they were present in all
(Continued on next page)
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blaVIM-2 (26/130, 20.0%), and blaVIM-8 (1/130, 0.8%). Interestingly, some of these genes
were restricted to certain CNPA clones, including the blaGES-5, blaIMP-1, blaIMP-43,
blaOXA-10, and blaVIM-8 genes that were found only in ST235, while ST823 was the only
sequence type harboring blaVIM-2. As expected, strains carrying these carbapenemase
genes had high imipenem and meropenem MIC values (Fig. 2B, subplots 1 and 2).
The mutational analysis of OprD revealed 32 different missense mutations, including
insertions leading to frameshifts (Fig. S2). Only one isolate had an OprD sequence
identical to that of the type strain PAO1; the rest were found to have accumulated a
pattern of point mutations that led to amino acid changes in the primary protein
structure of the OprD porin. Eight of the 32 amino acid substitutions were present in
more than 50% of the analyzed isolates, including the following: T103S (83/130, 63.9%),
K115T (83/130, 63.9%), F170L (82/130, 63.0%), E185Q (118/130, 90.8%), P186G (116/130,
89.2%), V189T (118/130, 90.8%), R310E (92/130, 70.8%), and A315G (88/130, 67.7%).
Details of the results of analyses of the amino acid substitution patterns can be found
in Table S4. We observed that in carbapenemase-nonproducing strains, certain OprD
types were prone to have higher imipenem and meropenem MIC values (Fig. 2B), but
we could not establish a conclusive correlation between these porin gene mutations
and the phenotypic susceptibility patterns of the CNPA strains.
Four different AMR determinants known to confer reduced susceptibility to quino-
lones were found. The gyrA modiﬁcation that confers resistance to quinolones in P.
aeruginosa (through the T83I amino acid substitution) was present in 105/130 (80.8%)
strains, all of which belonged to the prevalent ST235, ST357, and ST823 clones and to
minor clone ST244. The T83I amino acid substitution in gyrA was present in all strains
that had MICs of4 mg/liter for ciproﬂoxacin (Fig. 2B, subplot 3). Two additional amino
acid substitutions (H148N and D682E) were found in this gene. Additional mutations
were found in genes gyrB, parC, and parE (see Table S4). The aminoglycoside resistome
of the collection constituted 21 different aminoglycoside-modifying enzymes and their
variants, but the most prevalent aminoglycoside resistant determinant was chromo-
somally encoded APH(3=)-IIb, which was present in all strains. Additionally, we detected
mutations in mexZ and fusA1, both genes previously linked to aminoglycoside resis-
tance (15) (see Table S4). We observed that all these genes were associated with various
levels of susceptibility to amikacin (Fig. 2B, subplot 4). Regarding polymyxin resistance,
we did not ﬁnd any of the plasmid-mediatedmcr genes. With RGI-CARD, we found only
three AMR determinants (arnA, basR, and basS). arnA is a component of the arnT operon
but was the only gene of the operon present. The response regulator gene (basR) of the
two-component regulatory system BasRS was absent in all strains belonging to the
prevalent clones ST357 and ST823 and to the minor clones ST1076, ST312, and ST3277.
We expanded this analysis with the mutational resistome, including other genes related
to polymyxin resistance. Finally, genes related to bicyclomycin, fosfomycin, and chlor-
amphenicol resistance (bcr-1, fosA, and catB, respectively) were present in all isolates of
the collection.
Genomic epidemiology. The optimal threshold for distinguishing isogenic CNPA
strains from other strains circulating in this clinical setting was found to be a difference
of5 in the number of single nucleotide polymorphisms (SNPs). Thus, isolates that had
core genome SNP proﬁle differences below this threshold were considered to belong
FIG 2 Legend (Continued)
isolates: APH(3=)-IIb (aminoglycoside resistance); blaOXA-50 (-lactam resistance); fosA (fosfomycin resistance); bcr-1 (bicyclomycin resistance); arnA and
basS (polymyxin resistance); catB (chloramphenicol resistance); pmpM (multidrug and toxic compound extrusion [MATE] transporter); emrE (small
multidrug resistance efﬂux pump); crpP (quinolone resistance); mexA-mexB-oprM plus mexR, nalC, and nalD plus cpxR plus ArmR (resistance-nodulation-
cell division [RND] efﬂux pump plus mexAB repressors plus mexAB activator plus mexR inhibitor); mexC-mexD-oprJ plus NfxB (RND efﬂux pump plus
mexCD-oprJ repressor);mexE-mexF-oprN plusmexT plusmexS (RND efﬂux pump plusmexEF activator plusmexT suppressor);mexG-mexH-mexI-opmD plus
soxR (RND efﬂux pump plus transcriptional activator); mexJ-mexK-opmH plus mexL (RND efﬂux pump plus mexJK repressor); mexM-mexN-oprM (RND
efﬂux pump); mexP-mexQ-opmE (RND efﬂux pump); mexV-mexW-oprM (RND efﬂux pump); muxA-muxB-muxC-opmB (RND efﬂux pump); triA-triB-triC-
opmH (RND efﬂux pump); mexY plus mexZ (RND efﬂux pump component plus mexXY transcriptional regulator). (B) Bar plots showing the relation
between the MIC of imipenem, meropenem, ciproﬂoxacin, and amikacin (subplots 1 to 4) and their related resistance genes found among the CNPA
according to the literature. Vertical red dashed lines mark the EUCAST 2019 resistance breakpoints.
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to the same (i.e., isogenic) strain present in this clinical setting. This cutoff value was
associated with a priori sensitivity and speciﬁcity values of 0.76 and 0.95, respectively
(Fig. 3).
This cutoff value of 5 SNPs was compatible with the median number of differences
in SNPs found between isolates belonging to the dominant multilocus sequence types
(MLSTs); these median (range) SNP differences were 59 (0 to 82) for strains belonging
to ST235, 17 (0 to 32) for ST357 strains, 5 (0 to 54) for ST446 strains, and 5 (0 to 54) for
ST823 strains. We observed several cases where multiple CNPA isolates cultured from
the same patient had the same multilocus sequence type but differed by more than the
threshold value of 5 SNPs, indicating that they were different strains circulating
independently from each other in this clinical setting at the time of the study. That
ﬁnding included patients with isolates that were acquired in the ICU and patients with
isolates that were imported into the ICU. Also, we observed that exclusion of prevalent
sequence types from the calculations had some impact on the optimal cutoff value
(Table S6), indicating that the genotypic composition of a collection of CNPA isolates
may generate (slightly) different optimal cutoff values. Using the 5-SNP threshold, the
possible transmission events (PTEs) occurred in the ICU setting at rates of 27.7/100
admissions and 38.0/100 admissions during the preintervention and postintervention
phases, respectively. However, the rates of acquisition events (AEVs) were much lower,
at 9.2/100 admissions in the preintervention phase and 11.8/100 admissions in the
postintervention phase. The majority of AEVs were from known sources. However,
FIG 3 (Top image) Receiving operator characteristics curve. The area under the curve value is represented at the
right corner of the image. (Bottom image) Cumulative distribution analysis showing the effects of variations in the
cutoff SNP values on sensitivity (blue line), speciﬁcity (red line), and the positive likelihood ratio (green line). A
vertical dashed black line shows the threshold corresponding to 5 SNP. A zoomed image of the ﬁrst 100 cutoffs
is displayed inside a box.
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sizable minorities of AEVs (38% and 42% in the respective phases of the study) were
from an unknown source. Data corresponding to the number of PTEs and AEVs from
known sources during the study period are presented in Fig. 4. Most transmission
events (PTEs and AEVs) occurred between patients within each of the two ICUs, but
such transmissions were also noted to have occurred between the two ICU wards.
Environmental sources were mostly linked to transmissions in the ER-ICU, although we
registered four PTEs linking adult ICU patients admitted during the preintervention
phase to CNPA-positive environmental samples cultured during the postintervention
phase, indicating long-term circulation of these strains in the ICU. Using either of the
two approaches, we did not ﬁnd a statistically signiﬁcant difference between the PTE
or AEV rates in the preintervention period versus the postintervention period (P values
of 0.05). However, the observed number of AEVs in the adult ICU dropped from six
to zero in the preintervention period versus the postintervention period. In contrast,
the number of AEVs increased from 8 to 17 in the ER-ICU at the same time. Similar
contrasting trends were observed while tracing PTEs.
Finally, the calculated Hill numbers for the CPNA isolates collected in the preinter-
vention and postintervention phases were found to have increased (0D, 20 and 29,
respectively; 1D, 10 and 20, respectively; 2D, 7 and 17, respectively), indicating
that the genotypic diversity among the CNPA isolates cultured during the postinter-
vention phase had increased compared to the genotypic diversity of the collection
before the intervention.
DISCUSSION
In this study, carbapenem-nonsusceptible Pseudomonas aeruginosa (CNPA) strains
were found to be endemic in the ICUs of the Dr. Cipto Mangunkusumo General Hospital
in Jakarta, Indonesia. CNPA clones are present in the ICU environment and are regularly
being transmitted to and from patients and their immediate environment. We detected
four dominant P. aeruginosa clones (ST235, ST357, ST446, and ST823) which have
previously been shown to have spread worldwide and to carry a repertoire of antimi-
crobial resistance-related genes corresponding to resistance elements ranging from
carbapenemases (such as blaIMP or blaVIM) to defective outer membrane porins (see
FIG 4 (A) Potential transmission events (PTEs) and (B) acquisition events (AEVs) from known sources
during the study period. The boxes consisting of dashed lines represent the two intensive care units,
during the preintervention and postintervention phases (panels on the left and right, respectively).
Environmental sources of CNPA are depicted by green-colored sinks. Dashed lines represent transmis-
sions (both PTEs and AEVs) between the two study phases; note that such transmissions have been
registered as belonging to the postintervention phase.
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below). We also traced CNPA transmissions using whole-genome sequencing (WGS). To
do so, we distinguished isogenic CNPA strains by the use of a new methodology based
on the differences in the SNP proﬁles of their core genomes and on the patients from
whom they were cultured. An optimal SNP threshold—below which strains are con-
sidered isogenic—was calculated and then applied to trace transmissions of CNPA in
this setting. One approach identiﬁed potential transmission events based solely on
isogenic strains being cultured from different sites. In another approach, we addition-
ally used clinical data to infer CNPA acquisitions by patients during their ICU stay. The
latter approach helped us focus on CNPA transmission routes relevant for nosocomial
infection control.
We also assessed the impact of an infection control intervention that was imple-
mented in both ICUs to reduce transmissions of multidrug-resistant pathogens. We did
observe a large shift in the distribution of CNPA clones, together with an increase in the
genotypic diversity of the CNPA population. However, overall, the rates of acquisition
of CNPA strains by patients during their ICU stay did not change signiﬁcantly. Inter-
estingly and inexplicably, a reduced transmission rate in one ICU was accompanied by
an increased transmission rate of CNPA in the other ICU. Since the study did not include
comparator ICUs that were not intervened with, the observed changes might well be
a reﬂection of the natural variation in the epidemiological dynamics of CNPA in such
settings. Although the two ICUs were under same management, the ICUs are in
different buildings and have dedicated nursing staffs and also differ in their rates of
turnover of patients, all of which might have confounded the effects of the interven-
tion. Either prospective comparative study designs or quasiexperimental designs such
as interrupted time series analysis would be needed to come to more-deﬁnitive
evaluations of the effect of hygienic interventions on the epidemiology of CNPA in
intensive care units.
The four main sequence types described in the ICUs of this hospital in Jakarta
belong to the so-called P. aeruginosa high-risk international clones reported around the
globe that are associated with MDR proﬁles. Of the four, ST235 and ST357 have been
extensively reported in several countries (16–19), while the other two main STs, ST823
and ST446, emerged more recently. A recent study of MDR P. aeruginosa in Malaysia
also found ST235, ST357, and ST446 in a hospital setting (20). ST823 was previously
described as a minor sequence type found in a multicenter study undertaken in the
Gulf Cooperation Council states; more speciﬁcally, this clone was found among isolates
from Qatar and the United Arab Emirates (21). ST823 has also been found in India and
was shown to contain an atypically long genomic island harboring blaVIM-2 (22). ST446
has been isolated in small clusters or singletons in Spain, The Netherlands, eastern
France, and Belgium, showing MDR or carbapenemase-producing proﬁles (23–26).
None of the minor sequence types of CNPA in this study harbored genes coding for
carbapenemases, including the ST244 strains, which were linked to the production of
blaVIM-2 carbapenemase in a previous study in West and Central Africa (27). One of the
possible consequences of the intervention that we cannot readily explain is the
replacement of ST235 by ST357 as the dominant clone. We argue that this substitution
may have been the consequence of the intervention, which involved cleaning up
environmental sites and limiting transmission initially but was not able to maintain
hygienic vigilance over time (28). Alternatively, the waxing and waning of the levels of
different CNPA sequence types over time may be the rule rather than the exception in
ICUs, and this natural trend may not have been inﬂuenced much by the infection
control intervention applied in our ICU setting. In addition, we did not observe
signiﬁcant changes in the number and composition of AMR determinants in the two
sequence types, which argues against changes in antibiotic pressure having been a
direct cause of the replacement of the CNPA strains. Other hypotheses that we
contemplated included the possibility of changes in the virulence patterns, as de-
scribed previously by Bricio-Moreno et al. (29), or of different levels of susceptibility to
certain disinfectants such as chlorhexidine, as the use of chlorhexidine-based bathing
and mouthwash was part of the intervention.
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We wanted to see the full repertoire of AMR genes present in our collection, because
P. aeruginosa is well known for its capacity to expand its resistome, especially in
hospital settings, with the ICU as an important hot spot (30). In a recent study
determining the resistomes of 672 P. aeruginosa strains, Jaillard et al. identiﬁed 147 loci
associated with antimicrobial resistance, including associations between AMR markers
and antibiotics not described before (31). Around 40% of the AMR determinants
described in our collection overlapped those described by Jaillard et al. These differ-
ences might be explained by the huge diversity in the P. aeruginosa genome; i.e., over
30 different aminoglyoside resistance markers were present, plus mutations in other
AMR determinants such as mexZ or fusA1 could contribute to the global aminoglyco-
side resistance of the strains (15). Predictably, over two-thirds of the genotypically
unique strains (87/130, 66.9%) in our CNPA collection carried a carbapenem-degrading
enzyme. Back in 2015, Potron et al. (32) published a review focusing on the AMR
mechanisms and epidemiology of multidrug-resistant Acinetobacter baumannii and P.
aeruginosa which featured several tables that listed all known carbapenemases, includ-
ing those found in our study. Interestingly, while blaGES-5, blaIMP1-7-43, and blaVIM-2 had
been previously reported in Asian countries, including Japan, China, India, and Malay-
sia, blaVIM-8 had been previously reported only in Colombia in South America (33). To
our knowledge, this study is the ﬁrst to report this speciﬁc blaVIM-8 type outside South
America.
Another well-known mechanism of nonsusceptibility to carbapenems is a defective
OprD, an outer membrane porin in P. aeruginosa (34). We found several amino acid
substitutions and insertion and/or deletion events in the tertiary structure of the OprD
porin protein, but we could not associate them with speciﬁc resistance phenotypes. All
these point mutations have been previously described (35–37). Speciﬁc point muta-
tions (i.e., early stop codons) and frame shifts may be involved in the loss of the OprD
porin and, therefore, may affect carbapenem susceptibility (38, 39).
The spread of MDR Gram-negative bacteria carrying carbapenem resistance genes,
such as those described above, has been greatly inﬂuenced by several factors at the
local and global scales, including pathogen and host characteristics, antibiotic prescrip-
tion practices, and public health policies (40). Furthermore, there is increasing evidence
relating antibiotic consumption to the rise of AMR. A recent retrospective study in 153
tertiary hospitals in China signiﬁcantly correlated the use of carbapenems to the rate of
isolation of carbapenem-resistant Gram-negative bacteria, including P. aeruginosa (41).
To address this issue, antimicrobial stewardship programs (ASP) aimed at optimizing
the use of broad-spectrum antibiotics have been set up in different forms and contexts
(42). According to a recent meta-analysis, ASP outcomes translate to smaller amounts
of broad-spectrum antibiotics consumed and fewer infections by MDR microorganisms,
among other beneﬁts (43). As an example, an ASP to restrict the use of carbapenems
was implemented in the ICU of a Saudi Arabian hospital, effectively reducing the
prevalence of MDR strains among the P. aeruginosa isolates (44).
Until a few years ago, hospitals from high-income countries relied on techniques
such as pulsed-ﬁeld gel electrophoresis (PFGE) to classify nosocomial pathogens into
genetically closely related groups called genotypes, such that their epidemiology could
be ascertained. However, WGS provides maximum discriminatory power and is deemed
able to unequivocally assign identity to them (45). Two WGS typing approaches have
emerged: (i) multilocus sequence typing based on whole/core genomes (wg/cgMLST)
and (ii) analysis of single nucleotide polymorphisms across the whole/core genome
(wg/cgSNP) (46, 47). Our typing method, based on cgSNPs and clinical data, depends
on the quality of each of these data sources. The calculated optimal SNP threshold
value depends to some degree on the genotypic composition of the collection of
isolates under analysis. We have shown that the diversity of a bacterial population may
inﬂuence this cutoff value, although it remains fairly similar to the threshold of 4 SNPs
established in other studies (11, 48). Thus, there may not be a single optimal SNP cutoff
value to distinguish isogenic strains across different collections of P. aeruginosa. How-
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ever, an optimal SNP cutoff value can be derived for each collection using the new
method that we describe in this report.
We would like to point out some other limitations in our study design, the main
being the relatively small number of environmental isolates included. Environmental
samples were taken only once during each of the two phases of the study. Thus, much
more frequent environmental sampling is needed, as was done for the patients
themselves, to better detect the niches and transmission routes of CNPA in the intrinsic
environment of the ICUs. Similarly, each of the health care personnel was sampled only
twice, which may not have been a sufﬁciently sensitive method to exclude their
potential role as a (intermediate) reservoir, source, or vector of CNPA. Another issue is
that we did not target carbapenem-susceptible P. aeruginosa (CSPA); doing so would
have allowed a deeper understanding of the role of resistance genes in the epidemi-
ology of P. aeruginosa in this health care setting and would have further clariﬁed the
development of the resistome of this important nosocomial pathogen. Finally, all our
calculations were made using a couple of custom Python scripts and some manual
counting. This makes the process not fully automated and, in its present form, not fully
scalable. Further steps to improve the scalability and reproducibility of this methodol-
ogy are necessary.
Conclusions. Using whole-genome sequencing in combination with clinical data,
we were able to closely track and trace the endemic spread of isogenic carbapenem-
nonsusceptible strains of Pseudomonas aeruginosa over a 3-year period in the ICUs of
a single tertiary care hospital in Indonesia, a large tropical middle-income country. We
observed signiﬁcant changes in the clonal composition of CNPA and provide insight
into the dynamics of transmission of these strains over time but are unable to directly
ascribe these changes to the infection control interventions applied. Additionally, we
detected the presence of high-risk international clones of multidrug-resistant P. aerugi-
nosa in Indonesia and present their resistomes.
MATERIALS AND METHODS
Ethics approval. The Ethics Committee of the Faculty of Medicine, Universitas Indonesia, approved
the research on 17 September 2012 (approval no. 561/PT02.FK/ETIK/2012 and 757/UN2.F1/ETIK/X/2014).
Informed consent was documented by the use of a written consent form that was approved by the Ethics
Committee Faculty of Medicine Universitas Indonesia/Dr. Cipto Mangunkusumo General Hospital and
that was signed and dated by the subjects or their guardians and by the person who conducted the
informed consent discussion and two witnesses. The signature conﬁrmed that the consent was based on
information that had been understood.
Study design—sample collection.We performed a prospective, quasiexperimental before-and-after
study in two ICUs of the national referral hospital of Indonesia. Dr. Cipto Mangunkusumo Hospital is a
1,200-bed university hospital located in Jakarta. We conducted this study in two ICUs for adult patients,
the 12-bed adult ICU and the 8-bed emergency room ICU (ER-ICU), with averages of 1,010 and 415
admissions per year, respectively. Both ICUs have an open ward design. The populations served by these
two ICUs were very similar, and there was also no difference in the care provided (8). The study consisted
of three study phases, namely, a preintervention phase (April to October 2013 and April to August 2014),
an intervention phase (December 2014 to January 2015), and a postintervention phase (February to
December 2015) (8, 28).
CNPA strains were collected from clinical cultures and by targeted screening in the preintervention
and postintervention phases. Health care personnel and the ICU environment were screened for CNPA
as well (once each in the preintervention and postintervention phases of the study). A list of the isolates,
together with clinical data, can be found in Table S5 in the supplemental material. All isolates were stored
in 10% glycerol-containing media and were frozen at –80°C until further use. This study has been
registered at www.trialregister.nl (no. 5541; candidate no. 23527; Netherlands Trial Register [NTR] trial no.
NTR5541; date of NTR registration, 22 December 2015). Further details on the wards for the period 2013
to 2014, the sampling process, and the microbiological methods, such as the CNPA selection criteria,
have been previously described in detail (8). Replicate collections of all these isolates were archived in
Jakarta (Indonesia), Rotterdam (The Netherlands), and La-Balme-les-Grottes (France).
Intervention. Between the two collection periods mentioned above, an infection control bundle
aimed at reducing transmission of carbapenem-nonsusceptible P. aeruginosa, Klebsiella pneumoniae, and
Acinetobacter baumannii-Acinetobacter calcoaceticus complex was implemented in both ICUs. The mea-
sures adopted with this intervention included enhanced environmental cleaning, enforced antibiotic
stewardship (including daily evaluation of all antibiotic prescriptions on weekdays), and a targeted hand
hygiene education for health care workers of the ICUs (28). Once-daily bathing with chlorhexidine 2%
was introduced; for intubated patients, oral hygiene procedures were performed four times per day by
rinsing with 2% chlorhexidine solutions. Patients colonized or infected with carbapenem-nonsusceptible
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Gram-negative bacteria were grouped together in a dedicated area of the ward, with contact isolation
precautions performed as recommended by the CDC (https://www.cdc.gov/infectioncontrol/basics/
transmission-based-precautions.html).
Bacterial identiﬁcation, antibiotic susceptibility testing, and DNA extraction. Stored strains were
regrown from the –80°C stocks using Columbia agar plus 5% sheep blood (COS plates; bioMérieux,
Marcy-l’Étoile, France) and colonies conﬁrmed to contain Pseudomonas aeruginosa using Vitek MS with
standard acquisition parameters according to the instructions of the manufacturer (bioMérieux). Anti-
biotic susceptibility testing (AST) was performed with Vitek 2 (bioMérieux) using EUCAST 2019 break-
points (49). The antibiotics tested were ticarcillin, piperacillin, ticarcillin-clavulanic acid, piperacillin-
tazobactam, ceftazidime, cefepime, imipenem, meropenem, aztreonam, ciproﬂoxacin, levoﬂoxacin,
amikacin, gentamicin, and tobramycin. Susceptibility to colistin was not reported, since a validated
automated test to do so was lacking.
Whole-genome sequencing and bioinformatics. DNA was extracted from pure cultures using an
UltraClean microbial DNA isolation kit (Qiagen N.V., Venlo, The Netherlands), and quantity and quality
were assessed using a Qubit double-stranded DNA (dsDNA) BR assay kit (Thermo Fisher Scientiﬁc,
Waltham, MA, USA).
(i) Whole-genome sequencing methods and quality control. Samples from the preintervention
phase were sequenced using either a HiSeq 2500 instrument (Illumina Inc., Cambridge, United Kingdom)
with 150-bp paired-end reads or a MiSeq instrument (Illumina Inc.) with 200-bp paired-end reads.
Samples from the postintervention phase were sequenced using a NextSeq 500 instrument (Illumina
Inc.), with 150-bp paired-end reads. A Nextera XT DNA library preparation kit (Illumina Inc.) was used in
all cases. Paired-ended reads were assembled into contigs and scaffolds using the A5-MiSeq pipeline
(v20160825) (50). Correct identity of assemblies was conﬁrmed by average nucleotide identity (ANI)
analysis using FastANI (v1.2) (51), with P. aeruginosa PAO1 as the reference (GenBank accession no.
NC_002516.2). QUAST (v5.0.2) was run to assess the assemblies quality, using standard parameters and
with the inclusion of the “–scaffold” parameter when scaffolds were obtained from the assembly (14).
Reads and assemblies from all sequenced samples are available at the European Nucleotide Archive
website under project identiﬁers (IDs) PRJEB30625 and PRJEB32907, for the clinical and environmental
samples, respectively.
(ii) Antimicrobial resistance and MLST typing. Antimicrobial resistance determinants were iden-
tiﬁed from assemblies using the Resistance Gene Identiﬁer (RGI) command line tool associated with the
Comprehensive Antimicrobial Resistance Database (52–54) (updated in 2018; analysis date, December
2018), using the “Strict algorithm,” which allows the detection of previously unknown AMR genes. To
display the results obtained using the RGI tool, we used a cluster map created with a custom Python 3
script. Additionally, we screened the literature for genes belonging to the mutational resistome of P.
aeruginosa and analyzed them using Snippy (v1.4.1) (Seemann T [2015] snippy: fast bacterial variant
calling from NGS reads [https://github.com/tseemann/snippy]) by aligning the contigs to the P. aerugi-
nosa PAO1 reference genome (GenBank accession no. NC_002516.2) and selecting missense variants with
a minimum coverage of 50. BioNumerics 7.6 (Applied Maths, St-Martens-Latem, Belgium) was used for
in silico multilocus sequence typing (MLST) using the pubMLST database site (hosted at https://pubmlst
.org by the University of Oxford). goeBURST was used to infer the relatedness of the MLST proﬁles (55).
(iii) Genomic epidemiology of the bacterial strains. We used the assemblies to perform a
k-mer-based SNP analysis using kSNP3 (v3.01) (56). kSNP3 was executed with the parameters “–k 21
–core,” setting the k-mer nucleotide length to 21 bp and allowing the calculation of the “core SNPs.” The
“core SNPs” were those identiﬁed from k-mers present in all input samples. The goal was to use the SNP
data and the available clinical information to infer patterns of transmission of individual CNPA strains
between patients during the whole study period. To do so, the ﬁrst step was to determine a similarity
SNP cutoff value below which all isolates would be considered genetically identical, i.e., isogenic. From
among all of the kSNP3 output ﬁles, we chose the ﬁle containing the k-mer core SNPs detected
(“core_SNP_matrix.fasta”) and used it as the input ﬁle for snp-dists (v0.6; https://github.com/tseemann/
snp-dists). snp-dists was executed with the “–a –b” parameters. We used the pairwise SNP matrix to
evaluate different SNP thresholds. To calculate the optimal SNP threshold value, we assumed that truly
identical strains could be cultured only from the same patient and that different patients never shared
the same strain. Thus, we considered a true positive (TP) match to have been identiﬁed when the number
of SNP differences between two isolates from the same patient was below or equal to the tested
threshold, a true negative (TN) when the number of SNP differences between two isolates from different
patients was above the tested threshold, a false positive (FP) when the number of SNP differences
between two isolates from different patients was below or equal to the tested threshold, and a false
negative (FN) when the number of SNP differences between two isolates from the same patient was
above the tested threshold. Using a custom Python script, we counted the number of true positives (TPs),
true negatives (TNs), false positives (FPs), and false negatives (FNs) and then calculated sensitivity and
speciﬁcity values for a large range of threshold values (0 to 20,000). Sensitivity and speciﬁcity values for
these different SNP thresholds were used to calculate and plot a cumulative distribution analysis ﬁgure
and receiver operating characteristic (ROC) curves to ﬁnally select the optimal similarity SNP cutoff value
using Youden’s index. Isolates that had numbers of SNP proﬁle differences below this cutoff value were
considered to be isogenic, i.e., to represent the same strain circulating in this ICU setting at the time of
the study. We also evaluated the effect of adjusting the genotype distribution of the CNPA collection on
the optimal SNP cutoff value by similarly calculating optimal SNP cutoff values for different subcollec-
tions of our initial panel of P. aeruginosa isolates.
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(iv) Possible transmission events versus acquisition events. In order to highlight the importance
of clinical metadata in the outcome and interpretation of the genomic epidemiology analysis, we
differentiated between two approaches to account for transmissions of CNPA strains in the ICU setting.
The ﬁrst approach took into account only the genetic concordance between isolates based on SNP
differences generated by WGS, yielding what we called “possible transmission events” (PTEs). We deﬁned
a PTE as representing the identiﬁcation of two isolates cultured from two different patients—or from a
patient and an environmental sample—that were genetically considered to be the same (isogenic)
because the SNP proﬁles of their core genomes differed by less than the SNP cutoff value (see above).
In the second approach, we incorporated both genetic concordance and clinical and other laboratory
data, such as patient identiﬁer (ID), date of the culture, and patient admission and discharge dates, to
generate what we called acquisition events (AEVs). A patient was considered to have acquired a CNPA
in the ICU only when screening at admission was negative and the ﬁrst CNPA was isolated from a sample
taken at least 48 h after admission to the ICU. A patient could have an AEV representing acquisition from
either a known or an unknown source. An AEV from a known source was deﬁned as representing an
instance in which (i) a patient acquired a CNPA strain that was genetically the same (as deﬁned above)
as an isolate cultured earlier from another patient or from an environmental site and (ii) the clinical and
microbiological data (e.g., sampling date) could not exclude the possibility that a transmission had
occurred between them. If the origin of a CNPA strain cultured from a given patient could not be traced
back to a previously identiﬁed source, we labeled this AEV “from an unknown source.” To calculate either
PTE or AEV, we considered only the ﬁrst/earliest CNPA strain isolated; subsequent isogenic isolates from
the same patient were ignored in enumerating the number of PTEs and AEVs. To compare transmissions
before and after the intervention, the occurrence of PTEs and AEVs was expressed as an attack rate, using
the total number of patients at risk of CNPA transmission for each period as the denominator. The
chi-square test was used to report signiﬁcance.
Finally, we also calculated the ﬁrst three Hill numbers (0D, 1D, and 2D) (57) as measures of diversity
for the CNPA collections cultured in each of the preintervention and postintervention phases. These Hill
numbers represent the following mathematically converted classic diversity indices: 0D, richness; 1D,
exponent of Shannon-Wiener’s diversity index; 2D, reciprocal of Gini-Simpson’s index.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.02384-19.
FIG S1, PDF ﬁle, 0.7 MB.
FIG S2, PDF ﬁle, 0.2 MB.
TABLE S1, XLSX ﬁle, 0.02 MB.
TABLE S2, XLSX ﬁle, 0.04 MB.
TABLE S3, DOC ﬁle, 0.05 MB.
TABLE S4, XLSX ﬁle, 0.1 MB.
TABLE S5, XLSX ﬁle, 0.1 MB.
TABLE S6, DOCX ﬁle, 0.01 MB.
ACKNOWLEDGMENTS
We thank the staff of the Department of Anesthesia and Intensive Care, Dr. Cipto
Mangunkusumo General Hospital, Jakarta, Indonesia, for their commitment and coop-
eration.
Y.R.S. is an awardee of the DIKTI-NESO Scholarship by The Directorate General of
Higher Education of Indonesia Ministry of Research, Technology and Higher Education
of the Republic of Indonesia, and of the Department of Medical Microbiology and
Infectious Diseases, Erasmus MC, Rotterdam, The Netherlands.
A.C.P. and M.P. received funding from the European Union’s Horizon 2020 research
and innovation program New Diagnostics for Infectious Diseases (ND4ID) under Marie
Skłodowska-Curie grant agreement no. 675412.
A.C.P., M.P., C.M., A.G., and A.V.B. are employees of bioMérieux, a company devel-
oping, marketing, and selling tests in the infectious disease domain. The company had
no inﬂuence on the design and execution of the clinical study and did not inﬂuence the
choice of the diagnostic tools used during the clinical study. The opinions expressed in
the manuscript are ours and do not necessarily reﬂect company policies.
A material transfer agreement (MTA) (no. LB.02.01/I.9.4/8500/2013) was reviewed
and approved by the Director of National Institute of Research and Development,
Ministry of Health, Indonesia.
Pelegrin et al. ®














1. Strateva T, Yordanov D. 2009. Pseudomonas aeruginosa—a phenomenon
of bacterial resistance. J Med Microbiol 58:1133–1148. https://doi.org/
10.1099/jmm.0.009142-0.
2. Labarca JA, Salles MJC, Seas C, Guzmán-Blanco M. 2016. Carbapenem
resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in
the nosocomial setting in Latin America. Crit Rev Microbiol 42:276–292.
https://doi.org/10.3109/1040841X.2014.940494.
3. Klockgether J, Cramer N, Wiehlmann L, Davenport CF, Tümmler B. 13
July 2011, posting date. Pseudomonas aeruginosa genomic structure and
diversity. Front Microbiol https://doi.org/10.3389/fmicb.2011.00150.
4. European Centre for Disease Prevention and Control. 2018. Surveillance
of antimicrobial resistance in Europe 2017. Annual report of the Euro-
pean Antimicrobial Resistance Network (EARS-Net). https://www
.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-
resistance-europe-2017.
5. Miyoshi-Akiyama T, Tada T, Ohmagari N, Viet Hung N, Tharavichitkul P,
Pokhrel BM, Gniadkowski M, Shimojima M, Kirikae T. 2017. Emergence
and spread of epidemic multidrug-resistant Pseudomonas aeruginosa.
Genome Biol Evol 9:3238–3245. https://doi.org/10.1093/gbe/evx243.
6. Treepong P, Kos VN, Guyeux C, Blanc DS, Bertrand X, Valot B, Hocquet D.
2018. Global emergence of the widespread Pseudomonas aeruginosa
ST235 clone. Clin Microbiol Infect 24:289–294. https://doi.org/10.1016/j
.cmi.2017.06.018.
7. Karuniawati A, Saharman YR, Lestari DC. 2013. Detection of carbapen-
emase encoding genes in Enterobacteriaceae, Pseudomonas aeruginosa,
and Acinetobacter baumannii isolated from patients at Intensive Care
Unit Cipto Mangunkusumo Hospital in 2011. Acta Med Indones 45:
101–106.
8. Saharman YR, Karuniawati A, Sedono R, Aditianingsih D, Sudarmono P,
Goessens WHF, Klaassen CHW, Verbrugh HA, Severin JA. 2018. Endemic
carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus
complex in intensive care units of the national referral hospital in
Jakarta, Indonesia. Antimicrob Resist Infect Control 7:5. https://doi.org/
10.1186/s13756-017-0296-7.
9. Kos VN, Déraspe M, McLaughlin RE, Whiteaker JD, Roy PH, Alm RA,
Corbeil J, Gardner H. 2015. The resistome of Pseudomonas aeruginosa in
relationship to phenotypic susceptibility. Antimicrob Agents Chemother
59:427–436. https://doi.org/10.1128/AAC.03954-14.
10. Hasman H, Saputra D, Sicheritz-Ponten T, Lund O, Svendsen CA, Frimodt-
Møller N, Aarestrup FM. 2014. Rapid whole-genome sequencing for
detection and characterization of microorganisms directly from clin-
ical samples. J Clin Microbiol 52:139–146. https://doi.org/10.1128/
JCM.02452-13.
11. Quick J, Cumley N, Wearn CM, Niebel M, Constantinidou C, Thomas CM,
Pallen MJ, Moiemen NS, Bamford A, Oppenheim B, Loman NJ. 2014.
Seeking the source of Pseudomonas aeruginosa infections in a re-
cently opened hospital: an observational study using whole-genome
sequencing. BMJ Open 4:e006278-10. https://doi.org/10.1136/bmj
open-2014-006278.
12. Freschi L, Jeukens J, Kukavica-Ibrulj I, Boyle B, Dupont MJ, Laroche J,
Larose S, Maarouﬁ H, Fothergill JL, Moore M, Winsor GL, Aaron SD,
Barbeau J, Bell SC, Burns JL, Camara M, Cantin A, Charette SJ, Dewar K,
Déziel É, Grimwood K, Hancock RE, Harrison JJ, Heeb S, Jelsbak L, Jia B,
Kenna DT, Kidd TJ, Klockgether J, Lam JS, Lamont IL, Lewenza S, Loman
N, Malouin F, Manos J, McArthur AG, McKeown J, Milot J, Naghra H,
Nguyen D, Pereira SK, Perron GG, Pirnay JP, Rainey PB, Rousseau S,
Santos PM, Stephenson A, Taylor V, Turton JF, Waglechner N, et al. 29
September 2015, posting date. Clinical utilization of genomics data
produced by the international Pseudomonas aeruginosa consortium.
Front Microbiol https://doi.org/10.3389/fmicb.2015.01036.
13. Saharman YR, Pelegrin AC, Karuniawati A, Sedono R, Aditianingsih D,
Goessens WHF, Klaassen CHW, van Belkum A, Mirande C, Verbrugh HA,
Severin JA. 6 August 2019, posting date. The epidemiology and charac-
terization of carbapenem-non-susceptible Pseudomonas aeruginosa in a
large intensive care unit in Jakarta, Indonesia. Int J Antimicrob Agents
https://doi.org/10.1016/j.ijantimicag.2019.08.003.
14. Gurevich A, Saveliev V, Vyahhi N, Tesler G. 2013. QUAST: quality assess-
ment tool for genome assemblies. Bioinformatics 29:1072–1075. https://
doi.org/10.1093/bioinformatics/btt086.
15. López-Causapé C, Rubio R, Cabot G, Oliver A. 27 March 2018, posting
date. Evolution of the Pseudomonas aeruginosa aminoglycoside muta-
tional resistome in vitro and in the cystic ﬁbrosis setting. Antimicrob
Agents Chemother https://doi.org/10.1128/AAC.02583-17.
16. Papagiannitsis CC, Matej Medvecky KC, Skalova A, Rotova V, Spanelova
P, Jakubu V, Zemlickova H, Zemlickova H, Czech Participants of the
European Antimicrobial Resistance Surveillance Network. 22 November
2017, posting date. Molecular characterization of carbapenemase-
producing Pseudomonas aeruginosa of Czech origin and evidence for
clonal spread of extensively resistant sequence type 357 expressing
IMP-7 metallo-beta-lactamase. Antimicrob Agents Chemother https://
doi.org/10.1128/AAC.01811-17.
17. Hong JS, Yoon E-J, Lee H, Jeong SH, Lee K. 2016. Clonal dissemination of
Pseudomonas aeruginosa sequence type 235 isolates carrying blaIMP-6
and emergence of blaGES-24 and blaIMP-10 on novel genomic islands
PAGI-15 and -16 in South Korea. Antimicrob Agents Chemother 60:
7216–7223. https://doi.org/10.1128/AAC.01601-16.
18. Del Barrio-Toﬁño E, López-Causapé C, Cabot G, Rivera A, Benito N,
Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N,
Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M,
González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Due-
ñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver
A. 24 October 2017, posting date. Genomics and susceptibility proﬁles of
extensively drug-resistant Pseudomonas aeruginosa isolates from Spain.
Antimicrob Agents Chemother https://doi.org/10.1128/AAC.02352-17.
19. Kainuma A, Momiyama K, Kimura T, Akiyama K, Inoue K, Naito Y,
Kinoshita M, Shimizu M, Kato H, Shime N, Fujita N, Sawa T. 2018. An
outbreak of ﬂuoroquinolone-resistant Pseudomonas aeruginosa ST357
harboring the exoU gene. J Infect Chemother 24:615–622. https://doi
.org/10.1016/j.jiac.2018.03.008.
20. Tada T, Hishinuma T, Watanabe S, Uchida H, Tohya M, Kuwahara-Arai K,
Mya S, Zan KN, Kirikae T, Tin HH. 25 April 2019, posting date. Molecular
characterization of multidrug-resistant Pseudomonas aeruginosa isolates
in hospitals in Myanmar. Antimicrob Agents Chemother 63:1–6. https://
doi.org/10.1128/aac.02397-18.
21. Zowawi HM, Syrmis MW, Kidd TJ, Balkhy HH, Walsh TR, Sm J, Al Jindan
RY, Alfaresi M, Ibrahim E, Al-Jardani A, Al Salman J, Dashti AA, Sidjabat
HE, Baz O, Trembizki E, Whiley DM, Paterson DL. 17 April 2018, posting
date. Identiﬁcation of carbapenem-resistant Pseudomonas aeruginosa in
selected hospitals of the Gulf Cooperation Council States: dominance of
high-risk clones in the region. J Med Microbiol https://doi.org/10.1099/
jmm.0.000730.
22. Botelho J, Roberts AP, León-Sampedro R, Grosso F, Peixe L. 2018. Car-
bapenemases on the move: it’s good to be on ICE. BioRxiv https://doi
.org/10.1101/392894.
23. García-Castillo M, Del Campo R, Morosini MI, Riera E, Cabot G, Willems R,
van Mansfeld R, Oliver A, Cantón R. 2011. Wide dispersion of ST175 clone
despite high genetic diversity of carbapenem-nonsusceptible Pseu-
domonas aeruginosa clinical strains in 16 Spanish hospitals. J Clin Mi-
crobiol 49:2905–2910. https://doi.org/10.1128/JCM.00753-11.
24. Cholley P, Thouverez M, Hocquet D, Van Der Mee-Marquet N, Talon D,
Bertrand X. 2011. Most multidrug-resistant Pseudomonas aeruginosa
isolates from hospitals in eastern France belong to a few clonal types. J
Clin Microbiol 49:2578–2583. https://doi.org/10.1128/JCM.00102-11.
25. Van der Bij AK, Van der Zwan D, Peirano G, Severin JA, Pitout JDD, Van
Westreenen M, Goessens WHF. 2012. Metallo--lactamase-producing
Pseudomonas aeruginosa in the Netherlands: the nationwide emergence
of a single sequence type. Clin Microbiol Infect 18:E369–E372. https://
doi.org/10.1111/j.1469-0691.2012.03969.x.
26. Bonnin RA, Bogaerts P, Girlich D, Huang T-D, Dortet L, Glupczynski Y,
Naas T. 25 May 2018, posting date. Molecular characterization of OXA-
198 carbapenemase-producing Pseudomonas aeruginosa clinical iso-
lates. Antimicrob Agents Chemother 62:1–7. https://doi.org/10.1128/
AAC.02496-17.
27. Cholley P, Ka R, Guyeux C, Thouverez M, Guessennd N, Ghebremedhin B,
Frank T, Bertrand X, Hocquet D. 2014. Population structure of clinical
Pseudomonas aeruginosa from West and Central African countries. PLoS
One 9:e107008. https://doi.org/10.1371/journal.pone.0107008.
28. Saharman YR, Aoulad Fares D, El-Atmani S, Sedono R, Aditianingsih D,
Karuniawati A, van Rosmalen J, Verbrugh HA, Severin JA. 3 June 2019,
posting date. A multifaceted hand hygiene improvement program on
the intensive care units of the National Referral Hospital of Indonesia in
High-Risk CNPA Clones Endemic to Indonesian ICUs ®













Jakarta. Antimicrob Resist Infect Control https://doi.org/10.1186/s13756
-019-0540-4.
29. Bricio-Moreno L, Ebruke C, Chaguza C, Cornick J, Kwambana-Adams B,
Yang M, Mackenzie G, Wren BW, Everett D, Antonio M, Kadioglu A. 2017.
Comparative genomic analysis and in vivo modeling of Streptococcus
pneumoniae ST3081 and ST618 isolates reveal key genetic and pheno-
typic differences contributing to clonal replacement of serotype 1 in
The Gambia. J Infect Dis 216:1318–1327. https://doi.org/10.1093/
infdis/jix472.
30. López-Causapé C, Cabot G, Barrio-Toﬁño E, Oliver A. 6 April 2018,
posting date. The versatile mutational resistome of Pseudomonas aerugi-
nosa. Front Microbiol https://doi.org/10.3389/fmicb.2018.00685.
31. Jaillard M, van Belkum A, Cady KC, Creely D, Shortridge D, Blanc B, Barbu
EM, Dunne WM, Zambardi G, Enright M, Mugnier N, Le Priol C, Schicklin
S, Guigon G, Veyrieras J-B. 2017. Correlation between phenotypic anti-
biotic susceptibility and the resistome in Pseudomonas aeruginosa. Int J
Antimicrob Agents 50:210–218. https://doi.org/10.1016/j.ijantimicag
.2017.02.026.
32. Potron A, Poirel L, Nordmann P. 2015. Emerging broad-spectrum resis-
tance in Pseudomonas aeruginosa and Acinetobacter baumannii: mech-
anisms and epidemiology. Int J Antimicrob Agents 45:568–585.
https://doi.org/10.1016/j.ijantimicag.2015.03.001.
33. Crespo MP, Woodford N, Sinclair A, Kaufmann ME, Turton J, Glover J,
Velez JD, Castañeda CR, Recalde M, Livermore DM. 2004. Outbreak of
carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a
novel metallo--lactamase, in a tertiary care center in Cali, Colombia. J
Clin Microbiol 42:5094–5101. https://doi.org/10.1128/JCM.42.11.5094
-5101.2004.
34. Chevalier S, Bouffartigues E, Bodilis J, Maillot O, Lesouhaitier O, Feuilloley
MGJ, Orange N, Dufour A, Cornelis P. 2017. Structure, function and
regulation of Pseudomonas aeruginosa porins. FEMS Microbiol Rev 41:
698–722. https://doi.org/10.1093/femsre/fux020.
35. Epp SF, Köhler T, Plésiat P, Michéa-Hamzehpour M, Frey J, Pechère JC.
2001. C-terminal region of Pseudomonas aeruginosa outer membrane
porin OprD modulates susceptibility to meropenem. Antimicrob Agents
Chemother 45:1780–1787. https://doi.org/10.1128/AAC.45.6.1780-1787
.2001.
36. Ocampo-Sosa AA, Cabot G, Rodríguez C, Roman E, Tubau F, Macia MD,
Moya B, Zamorano L, Suárez C, Peña C, Domínguez MA, Moncalián G,
Oliver A, Martínez-Martínez L. 2012. Alterations of OprD in carbapenem-
intermediate and -susceptible strains of Pseudomonas aeruginosa iso-
lated from patients with bacteremia in a Spanish multicenter study.
Antimicrob Agents Chemother 56:1703–1713. https://doi.org/10.1128/
AAC.05451-11.
37. Shu J-C, Kuo A-J, Su L-H, Liu T-P, Lee M-H, Su I-N, Wu T-L. 2017.
Development of carbapenem resistance in Pseudomonas aeruginosa is
associated with OprD polymorphisms, particularly the amino acid sub-
stitution at codon 170. J Antimicrob Chemother 72:2489–2495. https://
doi.org/10.1093/jac/dkx158.
38. Richardot C, Plésiat P, Fournier D, Monlezun L, Broutin I, Llanes C. 2015.
Carbapenem resistance in cystic ﬁbrosis strains of Pseudomonas aerugi-
nosa as a result of amino acid substitutions in porin OprD. Int J
Antimicrob Agents 45:529–532. https://doi.org/10.1016/j.ijantimicag
.2014.12.029.
39. Kos VN, McLaughlin RE, Gardner HA. 2016. Identiﬁcation of unique in-frame
deletions in OprD among clinical isolates of Pseudomonas aeruginosa. Pat-
hog Dis 74:ftw031. https://doi.org/10.1093/femspd/ftw031.
40. Bassetti M, Poulakou G, Ruppe E, Bouza E, Van Hal SJ, Brink A. 2017.
Antimicrobial resistance in the next 30 years, humankind, bugs and
drugs: a visionary approach. Intensive Care Med 43:1464–1475. https://
doi.org/10.1007/s00134-017-4878-x.
41. Yang P, Chen Y, Jiang S, Shen P, Lu X, Xiao Y. 2018. Association between
antibiotic consumption and the rate of carbapenem-resistant Gram-
negative bacteria from China based on 153 tertiary hospitals data in
2014. Antimicrob Resist Infect Control 7:137–137. https://doi.org/10
.1186/s13756-018-0430-1.
42. Cox JA, Vlieghe E, Mendelson M, Wertheim H, Ndegwa L, Villegas MV,
Gould I, Levy Hara G. 2017. Antibiotic stewardship in low- and middle-
income countries: the same but different? Clin Microbiol Infect 23:
812–818. https://doi.org/10.1016/j.cmi.2017.07.010.
43. Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. 2016. Systematic
review and meta-analysis of clinical and economic outcomes from the
implementation of hospital-based antimicrobial stewardship programs.
Antimicrob Agents Chemother 60:4840–4852. https://doi.org/10.1128/
AAC.00825-16.
44. Abdallah M, Badawi M, Amirah MF, Rasheed A, Mady AF, Alodat M,
Alharthy A. 2017. Impact of carbapenem restriction on the antimicro-
bial susceptibility pattern of Pseudomonas aeruginosa isolates in the
ICU. J Antimicrob Chemother 72:3187–3190. https://doi.org/10.1093/
jac/dkx273.
45. Nadon C, Van Walle I, Gerner-Smidt P, Campos J, Chinen I, Concepcion-
Acevedo J, Gilpin B, Smith AM, Man Kam K, Perez E, Trees E, Kubota K,
Takkinen J, Nielsen EM, Carleton H; FWD-NEXT Expert Panel. 8 June
2017, posting date. PulseNet International: vision for the implemen-
tation of whole genome sequencing (WGS) for global food-borne
disease surveillance. Euro Surveill https://doi.org/10.2807/1560-7917
.ES.2017.22.23.30544.
46. Schürch AC, Arredondo-Alonso S, Willems RJL, Goering RV. 2018. Whole
genome sequencing options for bacterial strain typing and epidemio-
logic analysis based on single nucleotide polymorphism versus gene-
by-gene-based approaches. Clin Microbiol Infect 24:350–354. https://doi
.org/10.1016/j.cmi.2017.12.016.
47. Quainoo S, Coolen JPM, van Hijum S, Huynen MA, Melchers WJG, van
Schaik W, Wertheim HFL. 2017. crossm whole-genome sequencing of
bacterial pathogens: the future of nosocomial outbreak analysis. Clin
Microbiol Rev 30:1015–1063. https://doi.org/10.1128/CMR.00016-17.
48. Parcell BJ, Oravcova K, Pinheiro M, Holden MTG, Phillips G, Turton JF,
Gillespie SH. 2018. Pseudomonas aeruginosa intensive care unit
outbreak: winnowing of transmissions with molecular and genomic
typing. J Hosp Infect 98:282–288. https://doi.org/10.1016/j.jhin.2017.12
.005.
49. EUCAST. 2019. Breakpoint tables for interpretation of MICs and zone
diameters, version 8.1 2017. http://www.eucast.org/clinical_break
points/.
50. Coil D, Jospin G, Darling AE. 2015. A5-miseq: an updated pipeline to
assemble microbial genomes from Illumina MiSeq data. Bioinformatics
31:587–589. https://doi.org/10.1093/bioinformatics/btu661.
51. Jain C, Rodriguez-R LM, Phillippy AM, Konstantinidis KT, Aluru S. 30
November 2018, posting date. High throughput ANI analysis of 90K
prokaryotic genomes reveals clear species boundaries. Nat Commun
https://doi.org/10.1038/s41467-018-07641-9.
52. McArthur AG, Waglechner N, Nizam F, Yan A, Azad MA, Baylay AJ, Bhullar
K, Canova MJ, De Pascale G, Ejim L, Kalan L, King AM, Koteva K, Morar M,
Mulvey MR, O’Brien JS, Pawlowski AC, Piddock LJV, Spanogiannopoulos
P, Sutherland AD, Tang I, Taylor PL, Thaker M, Wang W, Yan M, Yu T,
Wright GD. 2013. The comprehensive antibiotic resistance database.
Antimicrob Agents Chemother 57:3348–3357. https://doi.org/10.1128/
AAC.00419-13.
53. McArthur AG, Wright GD. 2015. Bioinformatics of antimicrobial resis-
tance in the age of molecular epidemiology. Curr Opin Microbiol 27:
45–50. https://doi.org/10.1016/j.mib.2015.07.004.
54. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, Lago BA,
Dave BM, Pereira S, Sharma AN, Doshi S, Courtot M, Lo R, Williams LE,
Frye JG, Elsayegh T, Sardar D, Westman EL, Pawlowski AC, Johnson TA,
Brinkman FSL, Wright GD, McArthur AG. 2017. CARD 2017: expansion
and model-centric curation of the comprehensive antibiotic resistance
database. Nucleic Acids Res 45:D566–D573. https://doi.org/10.1093/nar/
gkw1004.
55. Francisco AP, Bugalho M, Ramirez M, Carriço JA. 2009. Global optimal
eBURST analysis of multilocus typing data using a graphic matroid
approach. BMC Bioinformatics 10:152–115. https://doi.org/10.1186/1471
-2105-10-152.
56. Gardner SN, Slezak T, Hall BG. 2015. kSNP3.0: SNP detection and
phylogenetic analysis of genomes without genome alignment or
reference genome. Bioinformatics 31:2877–2878. https://doi.org/10
.1093/bioinformatics/btv271.
57. MacArthur RH. 1965. Patterns of species diversity. Biol Rev 40:510–533.
https://doi.org/10.1111/j.1469-185X.1965.tb00815.x.
Pelegrin et al. ®





ber 21, 2019 by guest
http://m
bio.asm
.org/
D
ow
nloaded from
 
